

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

**INSIDE INFORMATION**  
**SUSPENSION OF SPIN-OFF AND OVERSEAS LISTING**  
**OF GUANGZHOU PHARMACEUTICALS CO., LTD.**

This announcement is made by Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcements of the Company (the latest one being dated 4 July 2021) and the circular of the Company dated 9 October 2020 in relation to the proposed spin-off (“**Proposed Spin-off**”) by the Company and overseas listing of Guangzhou Pharmaceuticals Co., Ltd (“**GP Corp.**”), a subsidiary of the Company.

The Company hereby announces that, in view of the expiry of the Approval on the Issuance of Overseas Listed Foreign Invested Shares of Guangzhou Pharmaceuticals Co., Ltd. (issued by the China Securities Regulatory Commission) on 23 June 2022 and having considered the changes of capital market of Hong Kong, and in conjunction with the development plan of the Company and GP Corp., the Company and GP Corp. determine to suspend proceeding with the Proposed Spin-off after due and careful consideration. However, the Company and GP Corp. do not exclude that they may, after taking into account future market circumstances and their business development needs, re-consider proceeding with the Proposed Spin-off at the appropriate time.

Shareholders and potential investors of the Company should exercise caution when dealing in or investing in the shares or other securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 23 June 2022

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive Directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin and Mr. Huang Min as independent non-executive Directors.*